New research shows that the quality of communication between patients and doctors, at the time of prescribing the additional pharmacological treatment for type 2 diabetes (DM2), is associated with better personal care and greater well -being1.Entrodia ™ is the largest international survey that includes responses of 4,235 people with DM2 of 26 countries* among which is Spain.
The research has shown that patients with type 2 diabetes relate a good communication quality in the visit in which complementary treatment with personal care is added.They also show greater emotional well -being, a reduction in psychic discomfort associated with diabetes, an improvement in the frequency of exercise and diet, as well as greater therapeutic compliance.
“It is important for poorly controlled DM2 patients to adequately introduce the new associated pharmacological treatment.A motivating conversation with the doctor can make a big difference in subsequent personal care.Now we have data that demonstrates it, ”explains Matthew Capehorn, a Primary Care doctor of the United Kingdom and member of the Advisory Commission of Introdia ™.
The analysis of the conversations has indicated that patients distinguish three types of conversations with the doctor who contribute to the quality of communication: motivating, collaboration and discouraging.If doctors use motivating and collaboration communication, the perception of quality by patients significantly improves, while discouraging statements have the opposite effect.
The type of conversations that patients remember more frequently have also been studied and it is shown that motivating conversations are more remembered by patients since up to 85 % remembers them against only 53 % of the discouraging.
“The data show that doctors are doing a good job, since most of the time use motivating and collaborative communication and, less frequently, discouraging communications.However, conversations about associated pharmacological treatment can improve and help patients make the behavioral changes necessary to control type 2 diabetes, ”concludes Capehorn.
The Boehringer Ingelheim and Lilly Alliance in Diabetes has presented a total of 35 abstracts in the 75th edition of the American Diabetes Association (ADA) scientific sessions.In addition to the results of the Entrodia ™ study, it has offered new clinical and preclinical data of its treatments for type 2 diabetes, pickery and linagliptin.
Among the most prominent, results are included on the initial combinations of requesting and metformin, which is being studied for the treatment of adults with type 2 diabetes;and phase 3 tests on the safety and efficacy of linagliptin in patients with DM2 and coronary heart disease.
"Given the growing number of people who are being diagnosed with type 2 diabetes, there is a tremendous need for clinical research to ensure that the treatment options and approaches that are being studied can meet the diverse needs of patients," says Hans-J.Woerle, vice president, Head of Medicine of the Boehringer Ingelheim Metabolism Therapeutic Area.
In the Entrodia ™ survey, a combination of validated evaluation media and new research methods were used to evaluate the quality of care and identify key elements of communication between the doctor and the patient.It was done through an online questionnaire and telephone or personal interviews in the necessary cases.
